Previous 10 | Next 10 |
The following slide deck was published by ChemoCentryx, Inc. in conjunction with their 2021 Q3 earnings call. For further details see: ChemoCentryx, Inc. 2021 Q3 - Results - Earnings Call Presentation
ChemoCentryx (NASDAQ:CCXI) announces that the EMA's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending marketing authorization for the company’s TAVNEOS (avacopan). TAVNEOS is an orally administered selective complement 5a recept...
SAN CARLOS, Calif., Nov. 12, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending marketing authorization for the...
In a previous article , I had pointed at Aurinia Pharmaceuticals as a potential takeover candidate. Since then, the biopharma company has been rumored as an acquisition target for Bristol Myers Squibb , with other giants such as Roche Holdings and GlaxoSmithKline als...
Image source: The Motley Fool. ChemoCentryx, inc (NASDAQ: CCXI) Q3 2021 Earnings Call Nov 9, 2021 , 5:00 p.m. ET Operator Continue reading For further details see: ChemoCentryx, inc (CCXI) Q3 2021 Earnings Call Transcript
ChemoCentryx, Inc. (CCXI) Q3 2021 Earnings Conference Call November 09, 2021 5:00 PM ET Company Participants Lee Roth - Burns McClellan, IR Thomas Schall - President and Chief Executive Officer Susan Kanaya - EVP, Chief Financial and Administrative Officer Tausif Butt - EVP and COO Conference...
ChemoCentryx (NASDAQ:CCXI): Q3 GAAP EPS of -$0.32 beats by $0.13. Revenue of $17.7M (+247.1% Y/Y) beats by $4.72M. Press Release For further details see: ChemoCentryx EPS beats by $0.13, beats on revenue
-- U.S. Food & Drug Administration (FDA) approves TAVNEOS TM (avacopan) in ANCA-Associated Vasculitis in October -- -- TAVNEOS now launched in the U.S. -- -- TAVNEOS approved also in Japan; European CHMP opinion expected this month -- -- Pipeline ...
SAN CARLOS, Calif., Nov. 04, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced the abstracts accepted for presentation and publication as part of the annual meetings of the American Society of Nephrology (ASN) Kidney Week 2021 and American College of Rheumatology ...
MOUNTAIN VIEW, Calif., Nov. 02, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that the Company's third quarter 2021 financial results will be released after market close on Tuesday, November 9, 2021. ChemoCentryx executive management will host a conference cal...
News, Short Squeeze, Breakout and More Instantly...
AMGEN SUCCESSFULLY COMPLETES ACQUISITION OF CHEMOCENTRYX PR Newswire TAVNEOS ® (avacopan), a First-in-Class Medicine for Patients With Severe Active ANCA-Associated Vasculitis, Added to Inflammation Portfolio THOUSAND OAKS, Calif. , Oct. 20, ...
-- Planned posters and an oral presentation will highlight data from the trials that supported the approval of TAVNEOS ® (avacopan) for patients with ANCA-associated vasculitis; additional poster will cover expression of kidney C5aR -- SAN CARLOS, Calif., Oct. 17,...
-- Two poster presentations planned for CCX559, including results from ongoing Phase I clinical study in patients with advanced solid tumors, and preclinical evidence from murine model -- SAN CARLOS, Calif., Oct. 05, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), tod...